Author

J. Doroshow

Observed name: James H. Doroshow

Institution: National Cancer Institute

Observed institutions: National Institutes of Health, National Cancer Institute, Center for Cancer Research

OpenAlex ID: A5035133131

A phase 1 study of orally administered 5-fluoro-2’-deoxycytidine with tetrahydrouridine in patients with refractory solid tumors

2025 · Alice P. Chen, Shivaani Kummar, et al. · Cancer Chemotherapy and Pharmacology · 1

Abstract PS1-08-07: Final results from the Randomized Phase II study of Z-Endoxifen and Tamoxifen in Endocrine Refractory, Estrogen Receptor Positive, HER2 negative Metastatic Breast Cancer (Alliance A011203)

2026 · M. P. Goetz, V. Suman, et al. · Clinical Cancer Research

49MO Atezolizumab and bevacizumab in patients treated with prior atezolizumab in alveolar soft tissue sarcoma (ASPS)

2023 · A. Chen, E. Sharon, et al. · ESMO Open

Abemaciclib drug combination screening with other targeted therapies in complex multicellular tumor spheroids

2022 · T. Dexheimer, T. Silvers, et al. · European Journal of Cancer

Works count: 4

Citation count: 1

H-index: 1

I10-index: